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ORIGINAL ARTICLE
Depletion of RUNX1/ETO in t(8;21) AML cells leads to
genome-wide changes in chromatin structure and
transcription factor binding
A Ptasinska1,2,8, SA Assi3,8, D Mannari4,9, SR James1,9, D Williamson5, J Dunne4, M Hoogenkamp1, M Wu6, M Care1, H McNeill5,
P Cauchy2, M Cullen1, RM Tooze1, DG Tenen6,7, BD Young4, PN Cockerill1,2, DR Westhead3, O Heidenreich5 and C Bonifer1,2
The t(8;21) translocation fuses the DNA-binding domain of the hematopoietic master regulator RUNX1 to the ETO protein.
The resultant RUNX1/ETO fusion protein is a leukemia-initiating transcription factor that interferes with RUNX1 function. The
result of this interference is a block in differentiation and, ﬁnally, the development of acute myeloid leukemia (AML). To obtain
insights into RUNX1/ETO-dependant alterations of the epigenetic landscape, we measured genome-wide RUNX1- and RUNX1/
ETO-bound regions in t(8;21) cells and assessed to what extent the effects of RUNX1/ETO on the epigenome depend on its
continued expression in established leukemic cells. To this end, we determined dynamic alterations of histone acetylation, RNA
Polymerase II binding and RUNX1 occupancy in the presence or absence of RUNX1/ETO using a knockdown approach.
Combined global assessments of chromatin accessibility and kinetic gene expression data show that RUNX1/ETO controls the
expression of important regulators of hematopoietic differentiation and self-renewal. We show that selective removal of
RUNX1/ETO leads to a widespread reversal of epigenetic reprogramming and a genome-wide redistribution of RUNX1 binding,
resulting in the inhibition of leukemic proliferation and self-renewal, and the induction of differentiation. This demonstrates that
RUNX1/ETO represents a pivotal therapeutic target in AML.
Leukemia (2012) 26, 1829--1841; doi:10.1038/leu.2012.49
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INTRODUCTION
Chromosomal rearrangements are a hallmark of hematopoietic
malignancies. Many of these translocations generate aberrant
transcriptional regulators that reproducibly lead to deﬁned blocks
in differentiation.1 A subclass of acute myeloid leukemia (AML) is
associated with a group of chromosomal translocations that each
result in disruption of the function of the core factor-binding (CBF)
complex, which consists of a heterodimer of RUNX transcription
factor family members and their binding partner CBFb.2 The best-
characterized CBF-type translocation is t(8;21), which fuses RUNX1
(AML1), a gene that is essential for normal hematopoiesis,3 with
the gene encoding transcriptional co-repressor ETO (RUNX1T1
or MTG8).4,5 The ectopic expression of RUNX1/ETO redirects
the speciﬁc gene expression program of normal precursor cells.6
The mechanism of such deregulation is based on RUNX1/ETO
interfering with normal RUNX1 function.7 - 11 However, the molecular
details of this interference are poorly understood on a genome-wide
level. Several studies have demonstrated that RUNX1/ETO acts as a
constitutive repressor by recruiting histone deacetylase complexes,
and that it interferes directly with other transcriptional regulators
of hematopoiesis such as C/EBPa.12 - 16 The presence of RUNX1/
ETO can alternatively lead to gene activation.17 - 20
The t(8;21) translocation is a leukemia-initiating event, and
fusion gene sequences can be found long before the onset of
leukemia in the blood from newborn children.21 However, the
induction of fully developed AML in t(8;21) patients requires
secondary genetic alterations,22 - 25 which complicates the estab-
lishment of in vitro model systems for gain-of-function studies.
In order to evaluate the suitability of RUNX1/ETO as a therapeutic
target, it is therefore necessary to identify its target sites at the
genome-wide level in actual leukemic cells, to deﬁne its indi-
vidual role in reprogramming gene expression networks and to
determine whether its continued presence is required for
maintaining deregulation. As RUNX1/ETO and RUNX1 occupy the
same binding sites, it is also important to elucidate how chromatin
and RUNX1 occupancy respond to loss of RUNX1/ETO binding
at its target genes.
To this end, we determined genome-wide patterns of
RUNX1/ETO occupancy in primary cells from patients and t(8;21)
cell lines, and compared histone acetylation proﬁles, RNA-
Polymerase II occupancy, RUNX1 binding and gene expression
before and after siRNA-mediated depletion of RUNX1/ETO. Global
loss of RUNX1/ETO binding results in widespread and complex
changes in chromatin structure patterns, RUNX1 occupancy and
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gene expression, indicating that RUNX1/ETO-mediated transcrip-
tional reprogramming is amenable to therapeutic intervention.
MATERIALS AND METHODS
Human primary cells and cell lines
Patient material was obtained with the required ethical approval from the
NHS Research Ethics Committees (Leeds Teaching Hospitals NHS Trust and
Newcastle upon Tyne Hospitals NHS Foundation Trust) or with informed
consent from adult patients at St Bartholomew’s Hospital, London.
The Kasumi-1 cell line was obtained from the DSMZ cell line repository
(http://www.dsmz.de/) and was cultured in RPMI1640 containing 10% fetal
calf serum. SKNO-1 cells were maintained in RPMI1640 supplemented with
20% FCS and 7ng/ml granulocyte --macrophage colony-stimulating factor.
RAW264.7 cells were cultured in Dulbecco’s modiﬁed Eagle’s Medium
containing 10% fetal calf serum.
siRNA transfections
Kasumi-1 and SKNO-1 cells and AML blasts were transfected with 200 nM of
siRNA using a Fischer EPI 3500 electroporator (Fischer, Heidelberg,
Germany) as described previously.26 For time course experiments,
sequential siRNA electroporations were performed at days 0, 4 and 7.
The following siRNAs were used: RUNX1/ETO siRNA (sense, 50-CCUCGAAAU
CGUACUGAGAAG-30 ; antisense, 50-UCUCAGUACGAUUUCGAGGUU-30), mismatch
control siRNA (sense, 50-CCUCGAAUUCGUUCUGAGAAG-30 ; antisense, 50-UC
UCAGAACGAAUUCGAGGUU-30).
RNA and protein isolation, real-time PCR and western blotting
RNA was isolated 2, 4, 7 and 10 days after siRNA electroporation using
RNeasy columns (Qiagen, Hilden, Germany). Total protein was precipitated
by adding two volumes of acetone to the ﬂow through of the RNeasy
columns and then resuspended in urea buffer (9 M urea, 4% (w/w)
3-((3-cholamidopropyl)-dimethylammonio)-propanesulphonate, 1% (w/w)
dithiothreitol). Reverse transcription, real-time PCR and western blotting
were performed as described.27
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using the
following antibodies: ETO (C-terminus-speciﬁc, Santa Cruz Biotechnology,
Wembley, UK, sc-9737X), RUNX1 (C-terminus-speciﬁc, Abcam, Cambridge,
UK, ab23980), RNA-Polymerase II phospho S2 (ab5095) and H3K9Ac
(ab4441).
DNase I hypersensitive site mapping
Genome-wide hypersensitive sites were mapped as described in Leddin
et al.28
Library generation and sequencing
Libraries of DNA fragments from ChIP or DNase I treatment were prepared
from B10 ng of DNA using standard procedures. DNA libraries were
subject to massively parallel DNA sequencing on an Illumina Genome
Analyzer (Illumina, Little Chesterford, UK).
Luciferase reporter assay
Reporter constructs were generated in the pGL4-Basic plasmid with
promoter sequences or in the pGL4-TK plasmid (Promega, Southampton,
UK) with distal sequences. Regions of interest were ampliﬁed from puriﬁed
genomic DNA from Kasumi-1 cells. Transient transfections of RAW264.7
cells were conducted using the Lipofectamine 2000 Reagent (Invitrogen,
Paisley, UK) according to the manufacturer’s protocol. Luciferase assays
were performed using a dual-luciferase reporter assay system (Promega).
Expression arrays
Total RNA was labeled and hybridized to the Illumina HT-12 v4 BeadChip
(Illumina).
Identiﬁcation of DNasel- and ChIP-sequencing peaks
The raw sequence data were aligned to the hg18 assembly (NCBI Build 36.1)
using BWA,29 and data were displayed using the UCSC Genome Browser.30
Regions of enrichment of DNaseI and ChIP data were identiﬁed using MACS
software.31 De novo motif analysis was performed using HOMER.32
Microarray gene expression data analysis
Microarray gene expression data were analyzed in GenomeStudio
software (Illumina) with background subtraction. The raw data output
was analyzed using the Lumi R package33 with quantile normalization. The
10% threshold (P-valuep0.1) was applied to all data. Genes were selected
with at least twofold change in expression.
Gene set enrichment analysis (GSEA) was performed using the
stand-alone application (Broad Institute) by ranking genes according to
their correlation (Pearson) with the F1 metagene, the metagene highly
expressed in the cells treated with siRNA for RUNX1/ETO. David/
EASE analysis was performed using the online tool at http:\\david.abcc.
ncifcrf.gov.34
A more detailed description of Methods is given in Supplementary
Material.
RESULTS
Identiﬁcation of high-conﬁdence binding sites for RUNX1/ETO and
RUNX1 in t(8;21) cells
In order to perform a comprehensive and stringent determination
of the chromatin and expression state of all genomic regions that
respond to the expression of RUNX1/ETO, we employed Kasumi-1
cells, a well-studied model of t(8;21) AML.27,35 This cell line was
obtained from a patient in second relapse after chemotherapy and
bone marrow transplantation, and thus represents the most
aggressive form of t(8;21) AML.35 Kasumi-1 does not express wild-
type ETO36 and still carries one intact RUNX1 allele. This permits
the discrimination between wild-type and translocated RUNX1
using antibodies against either the C terminus of RUNX1
recognizing only wild-type RUNX1, or the ETO moiety recognizing
only the RUNX1/ETO fusion. We identiﬁed a genome-wide set of
target sites for RUNX1 and RUNX1/ETO by ChIP followed by high-
throughput sequencing (ChIP sequencing; Figure 1, Supplemen-
tary Figure 1). To determine how RUNX1/ETO target genes
respond to loss of RUNX1/ETO binding and to evaluate
the speciﬁcity of peak calling, we performed ChIP sequencing
after speciﬁc RUNX1/ETO depletion using a siRNA that targets the
RUNX1/ETO junction within the transcript as well as both a
mismatch siRNA and mock transfection as controls. This knock-
down model system has been extensively validated and
characterized,17,24,26,27,36 - 40 and routinely leads to 470% reduc-
tion of all forms of the RUNX1/ETO protein (Figure 1a). A single
siRNA electroporation yielded a maximal RUNX1/ETO transcript
knockdown after 48 h. We therefore harvested siRNA-treated cells
at this time point for ChIP experiments.
To identify high-conﬁdence RUNX1/ETO targets regions, we ﬁrst
selected a set of 4598 ETO ChIP peaks that were shared between
mock-transfected and mismatch control-transfected cells
(Figure 1b). In all, 97% of these ETO ChIP peaks disappeared after
the speciﬁc knockdown of RUNX1/ETO (Figure 1b, Supplementary
Table 1). We have previously shown at speciﬁc genes that RUNX1/
ETO and RUNX1 bind within DNaseI hypersensitive sites (DHSs).7
To further increase peak conﬁdence, we therefore mapped DHSs
in Kasumi-1 cells (Supplementary Table 1) and show that475% of
both the RUNX1/ETO and also RUNX1 peaks were contained
within DHSs (Figures 1c and d). Annotating these peaks yielded
3633 target regions bound by RUNX1/ETO- and 6120 RUNX1-
bound regions. High-conﬁdence RUNX1/ETO peaks were located
in established target genes, such as CSF1R and IGFBP7 (data
not shown), the transcription factor genes NFE2, CEBPA, NOTCH1
and PU.1 (SPI1), and microRNA genes including MIR223 and the
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MIR23A---27A---24-2 cluster41 (Figure 1e, Supplementary Figure 1A).
High-conﬁdence peaks were also found between the telomerase
protein gene TERT and CLPTM1L, a locus associated with several
types of cancer42 (Supplementary Figure 1A, Supplementary Table
4). Selected peaks were validated manually in Kasumi-1 cells
(Supplementary Figures 1B and C) and in primary cells from a
t(8;21) AML patient (Supplementary Figures 1D--F), with and
without RUNX1/ETO knockdown.
To validate our genome-wide cell line ChIP-sequencing data, we
compared the RUNX1/ETO-binding pattern of Kasumi-1 cells to
that of primary, patient-derived t(8;21) AML cells. As with t(8;21)
cell lines, the wild-type ETO protein is neither expressed in t(8;21)-
negative nor in t(8;21)-positive AML cells,36,43,44 which agrees with
a lack of DHSs at the ETO (RUNX1T1) locus in all hematopoietic cell
types studied here (data not shown). With primary cells from two
patients (patients A and B), we obtained a large number of small
peaks, many of which disappeared when analyzed at higher
stringency (data not shown), but 2629 peaks occurred in both
patients. In all, 76% of joint peaks intersected with DHS from the
two other t(8;21) patients (no. 1 and no. 2, Supplementary Figure
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Figure 1. Identification of high-confidence binding sites for RUNX1/ETO and RUNX1. (a) Time course of RUNX1/ETO knockdown in Kasumi-1
cells. Top panel: real-time PCR analysis of mRNA expression; bottom panels: immunoblot detection of RUNX1/ETO protein. b-ACTIN served as
loading control. Time points are indicated at the bottom. RUNX1/ETO transcript levels are recovering 48 h after siRNA electroporation, whereas
protein levels remain low for another 24 h. siRE, RUNX1/ETO siRNA; siMM, mismatch siRNA; control, mock-transfected cells. (b) Intersection
analysis of RUNX1/ETO peaks. The Venn diagram shows the overlap between RUNX1/ETO peaks in mock, mismatch siRNA or RUNX1/ETO
siRNA-treated Kasumi-1 cells. The vast majority of RUNX1/ETO peaks were common to mock and siMM-treated Kasumi-1 cells, and 497% of
the common peaks disappeared after RUNX1/ETO depletion. (c, d) Identification of high-confidence peaks for RUNX1/ETO and RUNX1 in
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1G, Supplementary Table 1) and thus represented high-conﬁdence
peaks. More than 50% of genes bound by RUNX1/ETO in Kasumi-1
cells were also speciﬁcally bound in patient cells (Supplementary
Table 5). This high degree of concordance was also conﬁrmed by
comparing RUNX1/ETO binding to speciﬁc genes across the
genome (Figure 1e, Supplementary Figure 1A), including known
targets of RUNX1/ETO such as LAT2.45
RUNX1/ETO- and RUNX1-binding sites overlap only partially in
t(8;21) cells
Both RUNX1 and RUNX1/ETO showed a similar pattern of
distribution of binding sites for the subsets of peaks located
within 1.5 kb of transcription start sites, and 60% of the RUNX1/
ETO peaks overlapped with RUNX1 peaks (Figures 2a and b). The
unbiased de novo identiﬁcation of enriched consensus binding
motifs showed that, in contrast to RUNX1-unique peaks, both
RUNX1/ETO-associated and RUNX1/ETO-unique peaks were en-
riched in motifs for E-box-binding proteins (Figure 2c), in
agreement with observations that these factors form stable
interactions with the NHR1 domain of RUNX1/ETO.12 The same
motifs were found when examining the entire set of RUNX1- or
RUNX1/ETO-bound sequences in Kasumi-1 cells (Supplementary
Figures 2A and B). Both RUNX1/ETO- and RUNX1-binding regions
were enriched for RUNX1 consensus sequences, but only 30% of
RUNX1-unique peaks contained such motifs, indicating that at
c Motifs associated with
shared RUNX1/ETO 
and RUNX1 peaks in Kasumi-1 
Motifs associated with 
RUNX1 unique  
peaks in Kasumi-1 
Motifs associated with 
RUNX1/ETO unique 
peaks in Kasumi-1 
motif match score  (log p-value) 
ETS -1769 
ETS -1638 
ETS -1538 
  ETS -1418 
RUNX -1139 
RUNX -1111 
RUNX -948 
C/EBP -314 
motif match score  (log p-value) 
RUNX -1318 
ETS -1302 
ETS -1158 
RUNX -567 
ETS: 
E-box -437 
motif match score  (log p-value) 
RUNX -835 
ETS -682 
ETS -602 
E-box -489 
E-box -488 
E-box -447 
ETS -224 
b d
a
0
10
20
30
40
50
60
70
80
RUNX1 ETS E-box C/EBPα
%
 m
ot
ifs
 in
 p
ea
ks
 in
 K
as
um
i -
 1
RUNX1 & RUNX1/ETO 
overlap 
RUNX1 unique 
RUNX1/ETO unique 
RUNX1  
Kasumi-1  
(6120) 
RUNX1/ETO 
Kasumi-1  
(3633) 
2181 3939 1452 
10 3.5
3
2.5
2
1.5
1
0.5
RUNX1
in Kasumi-1
RUNX1/ETO
in Kasumi-19
8
7
6
5
4
3
2
%
 N
um
be
r o
f p
ea
ks
%
 N
um
be
r o
f p
ea
ks
1
-1500 -1100 -700
Distance from TSS Distance from TSS
-300 0 300 700 1100 1500 -1500 -1100 -700 -300 0 300 700 1100 1500
Figure 2. Identification and characterization of RUNX1/ETO and RUNX1 target regions in t(8;21) cells. (a) Positional distribution of RUNX1- (left)
or RUNX1/ETO- (right) binding sites relative to the transcription start site (TSS) of their nearest gene. (b) Intersection of RUNX1 and RUNX1/
ETO peaks in Kasumi-1 cells. The Venn diagram shows the numbers of high-confidence peaks bound by RUNX1 and RUNX1/ETO. (c) De novo
motif discovery performed on the set of regions bound by the RUNX1 and/or RUNX1/ETO in Kasumi-1 cells identified enriched RUNX
consensus and different types of ETS factor-binding sites. E-box motifs were significantly enriched in peaks either unique for RUNX1/ETO
or common to RUNX1/ETO and RUNX1. (d) RUNX, ETS, E-box and C/EBP consensus sequence were mapped back to all regions bound by
RUNX1/ETO and RUNX1. A large proportion of regions bound by RUNX1 did not contain RUNX (TGYGGT) and/or E-box (CANNTG) consensus
binding motifs, whereas most regions contain ETS (GGAW) sites.
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sites not occupied by RUNX1/ETO, RUNX1 may bind via interaction
with other transcription factors. These are likely to be ETS family
members, which present the top-scoring motif in this peak
population (Figure 2c). In contrast, up to 70% of shared and
unique RUNX1/ETO-bound sequences contained a RUNX1
motif (Figure 2d), suggesting that the fusion protein needs to
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Figure 3. RUNX1 in t(8;21)-positive and -negative leukemic cells associates with different binding sites motifs. (a) Identification of high-
confidence RUNX1 peaks from blasts from a AML patient with a normal karyotype (KN-AML). Venn diagram showing the intersection of
RUNX1 peaks with DHS. (b) Positional distribution of RUNX1-binding sites in KN-AML blasts relative to the transcription start site (TSS) of their
nearest gene. (c) Intersection of RUNX1 peaks in KN-AML cells and in Kasumi-1 cells. The Venn diagram shows the numbers of high-confidence
peaks bound by RUNX1. (d) RUNX1 consensus sequences were mapped back to all regions bound by RUNX1 in t(8;21)-negative AML blasts. A
large proportion of regions exclusively bound by RUNX1 contain RUNX, ETS and E-box consensus binding motifs as well as consensus binding
motifs for C/EBP and AP1. (e) De novo motif discovery performed on the set of regions bound by RUNX1 in t(8;21)-negative KN-AML blasts
identifies enriched RUNX and ETS consensus sequences as well as E-box, AP1- and C/EBP-binding sites.
Reversible epigenetic reprogramming by RUNX1/ETO
A Ptasinska et al
1833
Leukemia (2012) 1829 - 1841& 2012 Macmillan Publishers Limited
RUNX1 siMM 
Kasumi-1 
8368 
RUNX1 siRE
Kasumi-1
11827
61765651
2108 2634
RUNX1/ETO
control & siMM
4742
5134229 5138
Unique peaks
Shared peaks 
FGR NFIL3 
NFIL3
NFIL3
NFIL3
RUNX1/ETO control
_
RUNX1/ETO siMM 
_
RUNX1/ETO siRE
_
RUNX1
_
RUNX1 siMM
_
RUNX1 siRE
_
Sequence conservation
RUNX1 peaks unique
for siRE
5651
2192
RUNX1/ETO
control & siMM
4742
RUNX1 shared peaks
siRE & siMM
6176
4068
Figure 4. Knockdown of RUNX1/ETO leads to a redistribution of RUNX1 binding. Kasumi-1 cells were electroporated with either mismatch
control siRNA (siMM) or RUNX1/ETO siRNA (siRE). Two days after siRNA electroporation, RUNX1 binding was measured by ChIP sequencing in
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Figure 5. Analysis of RUNX1/ETO-dependent gene expression patterns. (a) Hierarchical clustering of genes responding by an at least twofold
change in expression levels to RUNX1/ETO knockdown in Kasumi-1 cells. The heat map shows early upregulated (Group I), downregulated
(Group II) and late upregulated genes (Group III) over a time course of 10 days. At the bottom of the heat map note non-clustered genes that
are either upregulated more than threefold or show a more complex response pattern (Group IV). Expression levels were compared between
RUNX1/ETO siRNA and mismatch siRNA-treated cells. Time points are indicated on the top of the heat map. Dark red indicates highly
upregulated genes and black indicates highly downregulated genes. (b) Effect of RUNX1/ETO depletion on gene expression in primary t(8;21)
AML blasts. The graph shows real-time PCR-based validation of early responding genes. The columns represent the means for three t(8;21)
AML patients and the error bars the s.e.m. Inset: immunoblot showing siRNA-mediated depletion of RUNX1/ETO in blasts from a t(8;21) AML
patient. (c) GSEA ranked according to the correlation of genes with a metagene (F1) summarizing the gene expression profile of Kasumi-1 cells
after RUNX1/ETO knockdown. From left to right: significant enrichment of gene sets downregulated in human hematopoietic stem cells upon
RUNX1/ETO overexpression6 and enrichment of genes determined in this study to have a high-confidence RUNX1/ETO-binding site
with a corresponding DHS in the region 2 kb upstream of the start of transcription in Kasumi-1 cells. P, nominal P-value; q, false discovery rate.
(d) The numbers of upregulated and downregulated genes upon RUNX1/ETO depletion in Kasumi-1 cells. The bottom row indicates
genes with RUNX1/ETO peaks. (e) Classification of RUNX1/ETO target genes. The columns show the percentage of genes with high-
confidence RUNX1/ETO peaks of all genes with changed gene expression upon RUNX1/ETO knockdown. siMM, mismatch siRNA; siRE, RUNX1/
ETO siRNA.
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be recruited by directly anchoring it to DNA. These results contrast
to recently published ﬁndings by Maiques-Diaz et al.,46
who reported a substantially lower fraction of RUNX1 motifs in
RUNX1/ETO peaks. This discrepancy may be due to the fact that
in these experiments a ChIP-chip proximal promoter array
was used.
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Differential binding of RUNX1 in AML cells without a CBF complex
mutation
The incomplete overlap between RUNX1 and RUNX1/ETO peaks
prompted us to investigate whether RUNX1 bound to different
sequences in the human genome in RUNX1/ETO-expressing cells
compared to AML cells without CBF mutations. To this end we
identiﬁed genome-wide high-conﬁdence RUNX1-binding sites in
AML cells with a normal karyotype (KN-AML) from a patient that
expressed a full-length RUNX1 protein (data not shown) but
displayed a block at a similar differentiation stage as the t(8;21)
patients and had a surface marker expression proﬁle highly similar
to the two t(8;21) AML samples (Supplementary Table 2). Similar to
Kasumi-1 cells, 90% of all RUNX1 peaks in the KN-AML blast cells
colocalized with DHSs (Figure 3a). Direct RUNX1 targets included
genes controlling hematopoietic differentiation such as CSF1R,
LAT2, and LMO2 (Supplementary Figure 3). The KN-AML RUNX1
peaks showed a similar pattern of distribution around the
transcription start sites as the RUNX1 peaks from Kasumi-1 cells
(Figure 3b), but their genome-wide distribution and enriched motif
composition was strikingly different. When directly compared
(Figure 3c), only 26% of the KN-AML RUNX1-binding sites were
found in Kasumi-1 cells. GATA3, GCHFR and KLF13 are examples for
this notion (Supplementary Figure 3). Most importantly, in contrast
to t(8;21) cells, the RUNX1 peaks unique for KN-AML showed a
highly signiﬁcant enrichment for binding sites for inducible
factors such as AP1, C/EBP and NF-kB (Figures 3d and e).
RUNX1/ETO knockdown leads to a shift in the pattern of RUNX1
occupancy
Our RUNX1 ChIP data indicate that the genome of hematopoietic
precursor cells contains a large number of functional RUNX1-
binding sites which are differentially occupied in t(8;21) AML and
KN-AML cells and are associated with different binding site motifs.
We therefore tested by ChIP sequencing whether depletion of
RUNX1/ETO led to an alteration of RUNX1 occupancy in RUNX1/
ETO expressing cells (Figure 4). The comparison between RUNX1
binding before and after knockdown showed that the depletion of
RUNX1/ETO led not only to an increase in the number of RUNX1
peaks, but also to the formation of a large number of de novo
RUNX1-binding sites (Figure 4a), as exempliﬁed by the transcrip-
tion factor gene NFIL3, which is upregulated by RUNX1/ETO
depletion (Figure 4b, right panel). Only 10% of de novo peaks
overlapped with RUNX1/ETO-bound sites (Figure 4a, bottom left).
In contrast, a much larger proportion (34%) of peaks shared
between knockdown and control samples were originally bound
by RUNX1/ETO (Figure 4a, bottom right). Interestingly, although at
most tested target regions depletion of RUNX1/ETO led to an
upregulation of RUNX1 binding and gene expression (an example
of this is shown with another upregulated gene, FGR, a member of
the SRC kinase family, in Figure 4b, left panel), this was not always
the case (Supplementary Figure 4). For instance, PU.1 (SPI1)
represents a class of genes, where RUNX1/ETO binding did not or
only marginally affect RUNX1 occupancy. The PU.1 upstream
regulatory element contains an upstream enhancer element (PU.1
(E)) that is bound by RUNX1 at multiple sites, and this binding is
vital for enhancer activity,47 but it is also bound by RUNX1/ETO
(this study). At this element RUNX1 binding did not respond to
RUNX1/ETO knockdown, and gene expression was barely altered,
which may indicate a complex binding pattern with multiple
occupancies of both RUNX1/ETO and RUNX1.
RUNX1/ETO depletion can lead to both activation and repression
of its direct target genes
In order to examine the effects of RUNX1/ETO depletion on gene
expression at the global level and to correlate these changes with
identiﬁed RUNX1/ETO target genes, we generated expression
proﬁles during a time course of sustained RUNX1/ETO knockdown
for 10 days in Kasumi-1 cells (Figure 5, Supplementary Table 6,
Supplementary Figure 5A). Hierarchical clustering identiﬁed four
groups of genes differentially responding to knockdown, consist-
ing of early (Group I) and late (Group III) upregulated genes,
downregulated genes (Group II) as well as genes showing a
complex pattern of response (Group IV; Figure 5a). These results
were validated by manual analysis with a selection of early
responding genes both in Kasumi-1 cells and in primary t(8,21)
cells obtained from three different AML patients (Figure 5b,
Supplementary Figure 5B).
To compare global gene expression proﬁles, we produced two
coordinately regulated metagenes F1 and F2 in an unsupervised
manner that summarized the expression of RUNX1/ETO-
dependent genes in a single score using non-negative matrix
factorization.48,49 The F1 and F2 metagenes were highly expressed
in Kasumi-1 cells with and without RUNX1/ETO knockdown,
respectively. We also tested the relevance of the RUNX1/ETO-
dependent global gene expression changes for another t(8;21)-
positive cell line, SKNO-1, and for primary t(8;21)-positive AML.
Kasumi-1-derived RUNX1/ETO-dependent metagene expression
was mirrored and validated in the SKNO-1 and primary AML data
sets, demonstrating an excellent concordance between the
RUNX1/ETO-associated global gene expression changes in these
three different t(8;21)-positive cell types (Supplementary Figure
5C). Furthermore, RUNX/ETO-associated gene expression changes
inversely correlated with gene expression changes observed in
previous knockdown studies and in overexpression studies with
primary human CD34þ cells (Figure 5c, Supplementary Figures
5D and E).6,27,39 These combined analyses conﬁrmed that RUNX1/
ETO-associated shifts in gene expression in Kasumi-1 faithfully
reﬂect gene expression features in the human t(8;21) AML.
The metagene was also used to rank genes for the purpose of
GSEA according to their correlation with the metagene score
(Supplementary Table 7). Genes with high-conﬁdence RUNX1/ETO
peaks were highly enriched in the RUNX1/ETO knockdown
signature (Figure 5c). However, not all genes responding to
RUNX1/ETO knockdown were associated with RUNX1/ETO peaks.
Genes responding early at day 2, such as CST7, IGFBP7 and MTSS1,
consisted of 50% direct RUNX1/ETO target genes, whereas this
was true for only 20% of the late responding genes at day 10
(Figures 5d and e). Moreover, almost 80% of all early responding
target genes were upregulated upon RUNX1/ETO knockdown, in
contrast to 60% of all late responding target genes (Figures 5d
and e). This indicates that downstream effects of the removal
of RUNX1/ETO contribute rapidly and progressively to the
reorganization of the transcriptional network.
The depletion of RUNX1/ETO leads to complex changes in the
histone acetylation pattern and RNA Polymerase II occupancy
As RUNX1/ETO recruits histone deacetylases to its target promo-
ters13,14 and alters gene transcription, we examined the immediate
consequences of RUNX1/ETO depletion on histone H3 lysine 9
acetylation (H3K9Ac) and occupancy of the elongating form of RNA
Polymerase II (RNA Pol II). We therefore performed ChIP experiments
with RUNX1/ETO-depleted and -control cells at day 2 after
knockdown, and integrated RNA Pol II and H3K9Ac data in
Kasumi-1 cells on RUNX1/ETO target loci with the gene expression
data (Figures 6a and b, Supplementary Table 6). After 2 days of
knockdown, half of the early upregulated genes, including IGFBP7,
NFE2 and PRG2, exhibited more than twofold increased RNA Pol II
occupancy, whereas most downregulated genes such as CD34 and
75% of the late upregulated genes generally showed no or little
change in RNA Pol II binding at this stage (Supplementary Figure 6A).
A more complex pattern of changes at RUNX1/ETO peaks
was seen when measuring H3K9Ac. Although after 2 days of
knockdown most upregulated genes displayed a rapid increase in
H3K9Ac, we also found an increase at 50% of the downregulated
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Figure 6. RUNX1/ETO silencing leads to changes in RNA-Polymerase II occupancy and the histone H3K9 acetylation pattern at RUNX1/ETO
target genes. (a) Comparison of RNA Pol II occupation with transcriptional profiling reveals a substantial correlation between changes in gene
expression and changes in RNA Pol II association upon RUNX1/ETO knockdown. RNA Pol II occupation was analyzed 48 h after siRNA
treatment, ranked according to fold change in occupancy and compared with changes in gene expression during a time course of 10 days
with siRNA treatment. Dark red indicates high occupancy or upregulation, black low occupancy or downregulation, respectively. (b) The
H3K9Ac pattern correlates partially with changes in gene expression associated with RUNX1/ETO depletion. H3K9Ac occupation was analyzed
and compared analogously to (a). (c, d) UCSC Genome Browser image of the human ZBTB16 and WT1 loci depicting ChIP-Seq tags for RUNX1/
ETO, RNA-Pol II and H3K9Ac in mock-treated (control), mismatch siRNA (siMM) and RUNX1/ETO siRNA (siRE)-treated Kasumi-1 cells. (e) Heat
map resulting from an unsupervised clustering of H3K9Ac- and RUNX1/ETO-binding sites with and without RUNX1/ETO knockdown (siMM
and siRE, respectively) as well as without transfection (control) showing two groups of sequences and their genomic location. In each lane, the
ChIP enrichment score is shown 10 kb upstream and downstream from the peak center. (f ) Integration of the sequence enrichment of each
group into a density plot showing the location of RUNX1/ETO-binding sites with and without knockdown in relation to H3K9Ac. Dark blue:
H3K9Ac (siMM); pink: H3K9Ac (siRE); green: RUNX1/ETO (control); yellow RUNX1/ETO (siMM); light blue: RUNX1/ETO (siRE).
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genes (Figure 6b). This group of down-regulated genes partially
overlapped with genes displaying an increase in RNA Pol II
occupancy (Figure 6a, Supplementary Figures 6B and C). Such
peaks were often localized in introns (for example, ZBTB16 or WT1,
Figures 6c and d) indicating that not all RUNX1/ETO peaks that are
associated with alterations of gene expression colocalize with
classical promoter or enhancer elements. This diversity was also
reﬂected in reporter gene assays of the promoters of target genes
(Supplementary Figure 6D): Many, but not all, of these promoter
elements directly responded to transactivation by RUNX1 and
repression by RUNX1/ETO.
We next used our histone acetylation data to examine the
chromatin architecture and the genomic distribution of RUNX1/
ETO-binding sites (Figures 6e and f). Unsupervised clustering
showed that RUNX1/ETO-binding sites could be clustered into two
groups (Figure 6e). The largest group contained intergenic and
intragenic sites that are most likely to be enhancers, as these
elements are also DNase I hypersensitive. The analysis of the
histone H3K9 acetylation proﬁle before and after knockdown
(Figure 6f) showed that in both groups the RUNX1/ETO complex
was ﬂanked by acetylated histones, demonstrating that histone
acetylation was not absent in such elements. This is consistent
with ﬁndings that described the presence of histone acetyl
transferases at these sites.7,20 However, the depletion of RUNX1/
ETO led to a strong increase in H3K9Ac, while maintaining a
protein complex between nucleosomes, demonstrating that
RUNX1/ETO does not lead to the formation of inactive chromatin,
but shifts the balance between active and inactive chromatin.
RUNX1/ETO depletion induces myeloid differentiation and silences
leukemic self-renewal programs
Finally, we asked which pathways and transcriptional programs
responded to regulation by RUNX1/ETO. Functional annotation
clustering separated RUNX1/ETO-bound genes from those exclu-
sively bound by RUNX1. In both primary cells and cell lines, genes
bound by the fusion protein are involved in processes, such as
cytoskeletal organization, cell adhesion and cell cycle control,
whereas genes solely bound by RUNX1 cluster with genes for
nuclear structures, translation-associated processes and RNA
processing (Supplementary Table 8). Genes responding to
RUNX1/ETO knockdown showed a link with cytoskeleton, cell
adhesion and migration, similar to those containing high-
conﬁdence RUNX1/ETO peaks (Supplementary Table 8). Moreover,
separate analysis for upregulated and downregulated genes
suggested an association of upregulated genes with differentia-
tion, whereas downregulated genes are involved in proliferation
and cell cycle regulation (Supplementary Table 9). These
combined analyses suggest that the downregulated RUNX1/ETO
genes are preferentially involved in proliferation and cell cycle
progression, whereas upregulated genes are involved in myeloid
differentiation. Indeed, suppression of RUNX1/ETO in t(8;21) AML
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cell lines impairs clonogenicity and proliferation, and leads to cell
cycle arrest in G1 phase.26
This notion is further supported by gene expression proﬁle
comparison and GSEA. Metagene-based comparison with global
gene expression proﬁles from cells of different normal human
hematopoietic differentiation stages50 demonstrate that Kasumi-1
cells depleted for RUNX1/ETO change their combined gene
expression pattern from a unique speciﬁc subset remotely
related to lymphoid and early myeloid precursors towards that
of the normal granulocyte/monocyte precursor, monocyte and
neutrophil subsets (Figure 7a).
GSEA showed that knockdown of RUNX1/ETO resulted in
signiﬁcant downregulation of cell cycle progression, telomere
maintenance genes and TERT target genes (Figure 7b, Supple-
mentary Figure 7A, Supplementary Table 7). In particular, the
inverse correlation between RUNX1/ETO knockdown and TERT
target gene expression supports a model of RUNX1/
ETO-controlled telomerase activity, a key factor of normal and
malignant self-renewal.37 In both t(8;21)-positive Kasumi-1 and
patient-derived primary AML cells, RUNX1/ETO binds to a region
between TERT and CLPTM1L implying TERT as a direct target gene
of RUNX1/ETO (Supplementary Figure 1A). Indeed, sustained
suppression of RUNX1/ETO caused an increasingly pronounced
inhibition of TERT expression over time in Kasumi-1 and in SKNO-1
cells (Figure 7c, Supplementary Figure 7B). Interestingly, in spite of
being highly activated particularly in MLL-rearranged leukemias,
HOXB and late HOXA genes may not be part of the RUNX1/ETO-
driven self-renewal program.51 In both t(8;21)-positive cell lines
and AML blasts, several HOXA members including HOXA9 as well
as the complete HOXB locus showed low or absent expression
levels and a lack of DHSs (Supplementary Figure 7C).
DISCUSSION
Gain-of-function studies using ectopic expression of RUNX1/ETO
in t(8;21)-negative leukemic and non-leukemic cells have yielded
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Figure 7. RUNX1/ETO knockdown interferes with leukemic self-renewal and promotes myeloid differentiation. (a) Comparison of F1 metagene
expression in normal hematopoietic sub-populations50 reveals high similarity between gene expression patterns of RUNX1/ETO-depleted
Kasumi-1 cells and those of monocytic and granulocytic cell types. The values of the F1 metagene for siMM-treated and siRE-treated Kasumi-1
cells are close to 0 and 1, respectively. Those colored red are cell types for which expression of the metagene is at least equal to RUNX1/ETO-
depleted Kasumi-1 cells indicating maximum similarity. (b) Gene set enrichment analysis using a ranking of TERT targets and their correlation
with the F1 metagene showing an inverse correlation of expression after knockdown.60 P, nominal P-value; q, false discovery rate. (c) RUNX1/
ETO depletion inhibits TERT expression. t(8;21)-positive Kasumi-1 were electroporated with either RUNX1/ETO or mismatch siRNA (siRE and
siMM, respectively) at day 2, 4, 7 and 10. RUNX1/ETO and TERT transcript levels were analyzed at the indicated time points by real-time PCR. The
color reproduction of this figure is available at the Leukemia journal online.
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insights into the molecular mechanisms of initiating leukemogen-
esis,6,46,52 - 54 whereas loss of function studies in actual leukemic
t(8;21) cells (including the Kasumi-1 cells described here) inform
about the role of RUNX1/ETO in maintaining leukemia.24,25,36,39
Our experiments and novel integrative data analyses demonstrate
a substantial concordance between these two approaches,
indicating that integral parts of the t(8;21)-speciﬁc leukemia-
initiating program are also required for maintaining the leukemic
phenotype. In both primary cells and cell lines, RUNX1/ETO
binds genes associated with the control of the cell cycle
and cell structure. Concordantly, siRNA-mediated depletion of
RUNX1/ETO affects transcriptional programs associated
with myeloid differentiation, proliferation and self-renewal,
in addition to those promoting cell cycle progression and DNA
synthesis.
Our siRNA knockdown shows that RUNX1/ETO binding leads to
large-scale, but reversible, alterations throughout the epigenome.
H3K9Ac at RUNX1/ETO-binding sites was mostly increased after
knockdown, which is consistent with a repressive role of the fusion
protein at these sites. However, RUNX1/ETO depletion was also
associated with upregulation of gene expression. In a recent
study, RUNX1/ETO was shown to also regulate gene activation in a
p300-dependent manner.20 Concurrent with this observation,
when combined with gene expression data, RUNX1/ETO depletion
concurred with strikingly complex regulatory patterns, with an
increase of H3K9Ac and RNA Pol II binding alterations being
associated with both upregulated and downregulated genes. An
illustrative example for this notion is the CD34 locus (Supplemen-
tary Figure 6C, lower panel), which contains an intragenic RUNX1/
ETO site and is downregulated by RUNX1/ETO depletion, but
shows increased histone acetylation at the main promoter. At the
WT1 locus, RUNX1/ETO binds to an element downstream of the
main start site that contains a bidirectional promoter driving an
alternative WT1 transcript and an inhibitory antisense intronic
transcript.55 RUNX1/ETO may therefore maintain WT1 expression
by repressing the expression of non-coding RNAs.55 This is of
signiﬁcant clinical interest because the level ofWT1 transcription is
a prognostic factor in leukemia diagnosis.56 Moreover, we also
found widespread siRNA-mediated changes in H3K9Ac at RUNX1/
ETO peaks that were not associated with alterations of steady-
state mRNA levels. These elements may represent sites that
respond to the upregulation of myeloid regulators such as C/EBPa
and prime genes for the onset of myeloid differentiation. Follow-
up of these observations is outside of the scope of this study, but
our datasets provide a wealth of resources for experiments
unravelling the mechanistic details of such changes.
Another important result from this study is our ﬁnding that the
depletion of RUNX1/ETO and subsequent cell differentiation is
associated with a redistribution of RUNX1-binding activity
throughout the genome. We observed a large number of new
binding sites distinct from those previously bound by RUNX1/ETO.
The induction of myeloid differentiation after RUNX1/ETO deple-
tion therefore involves not only loss of repression, but also
increased recruitment of transcriptional activators to additional
sites. Currently, we do not know how RUNX1 is directed to new
sites, but it is likely that this involves the interaction of RUNX1 with
other transcription factors whose activity is altered by RUNX1/ETO,
such as C/EBPa and PU.1.15,57 Our observation of a differential
binding of RUNX1 is also important in the context of leukemogen-
esis in general because it implies that mutations of RUNX1 that are
widespread in leukemogenesis and cause speciﬁc disease
phenotypes may differentially affect alternate subsets of genes
depending on how the interaction with cooperating transcription
factors is altered at each gene.58,59 Therefore, one of the future
challenges in leukemia research will be to unravel the differential
activity of transcription factors in a system-wide manner and to
model the regulatory consequences of such differences for each
speciﬁc type of leukemia.
In conclusion, our study demonstrates that epigenetic altera-
tions mediated by RUNX1/ETO are reversible at a global scale by
solely interfering with its function, emphasizing the feasibility
of targeted therapeutic approaches either using siRNA or small
molecules.
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